complain about the hypnopompic hallucinations, we continued olanzapine therapy for about 2 more months. The patient then started to complain more vociferously about sedation and continued to refer to the visual hallucinations mentioned above, which he had previously tolerated. Because these symptoms were totally discordant with the clinical picture drawn before treatment, we decreased the dosage from 20 to 15 mg, and then to 10 mg daily, over a 1-month period. Both sedation and hypnopompic hallucinations persisted at 10 mg daily, but above all, the clinical picture worsened, particularly with regard to social withdrawal. We therefore decided to discontinue olanzapine and replace it with risperidone.
We believe that olanzapine induced the hypnopompic hallucinations claimed by the patient. With regard to olanzapine's side effects, the drug literature has never reported imperceptive symptoms such as hypnopompic hallucinations. Conversely, cases of hypnopompic hallucinations have been reported during therapy with imipramine, amitriptyline, maprotiline, and donezepil. Schlauch has reported a case of hypnopompic hallucinations during therapy with imipramine and has suggested that such hallucinations may be connected to the decrease in rapid eye movement (REM) sleep caused by imipramine (1). Hemmingsen and Rafaelsen reported 4 cases of hypnopompic and hypnagogic hallucinations during therapy with amitriptyline (2) . According to these authors, there is a connection between amitriptyline effects on the brain, sleep patterns, and clinical condition. In our case, hallucinations appeared after a few days of treatment with olanzapine and continued for approximately 2 more months, manifesting themselves every morning as the patient woke up. The patient had never previously suffered hallucinations. They disappeared after the discontinuation of olanzapine therapy and did not reappear when another antipsychotic was administered.
The discontinuation of therapy was not determined by the hallucinations, which our patient tolerated, but by sedative side effects. Olanzapine at a dosage of 5 mg daily significantly increases slow wave sleep, probably by blocking 5-HT 2C receptors; it improves the continuity of sleep and the subjective quality of sleep. At a dosage of 10 mg, olanzapine significantly increases the latency of REM sleep and also decreases its duration. Such effects may be a consequence of the antagonist effects of olanzapine at muscarinic cholinergic receptors (3) . Inhibition of REM sleep, as we have mentioned above, is a common property of tricyclics.The manifestation of hypnopompic hallucinations caused by olanzapine could be similar to that described for tricyclics and is therefore probably linked to REM-sleep suppression.
Iginia Mancinelli, MD Maurizio Pompili, MD Amedeo Ruberto, MD Roberto Tatarelli, MD Rome, Italy
Atypical Neuroleptic Malignant Syndrome Caused by Clozapine and Venlafaxine: Early Brief Treatment With Dantrolene
Dear Editor: Clozapine can cause neuroleptic malignant syndrome (NMS) with a presentation that may be atypical in that it may occur without rigidity, fever, or changes in creatine kinase (CK) (1).
We report a case of possible atypical NMS arising from overdosage of clozapine and venlafaxine that was successfully treated with lorazepam and dantrolene.
Case Report
Mr A, aged 19 years, was diagnosed with shizoaffective disorder. Treatment for 2 years with clozapine 300 mg daily and venlafaxine 150 mg daily helped his condition. After he discontinued his medication for 2 weeks and then took 1000 mg clozapine and 900 mg venlafaxine, he presented to the emergency room, where he went into a coma and was admitted to the intensive care unit. His urine was positive for cannabinoids and clozapine but negative for alcohol, opiates, amphetamines, cocaine, and benzodiazepines. His temperature was 37.2EC.
The following day he emerged from coma and developed delirium, agitation, fluctuating blood pressure, a temperature of 38EC, and leukocytosis. He was without extrapyramidal signs (EPS) and had normal CK. Intravenous lorazepam 12 mg daily was added to his treatment. At day 3, his CK rose to 6700 U/L, and his myoglobin rose to 597 ng/L. Suspecting NMS, we added dantrolene 1 mg/kg 4 times daily. Twelve hours later, the patient's CK decreased to 3600 U/L. Glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) rose to 147 U/L and 91 U/L, respectively. After 3 more days, the patient's CK level was 1750 U/L, his temperature and myoglobin became normal, EPS were absent, consciousness was total, and paranoid delusion and depression emerged. Dantrolene was discontinued, and the patient was transferred to the psychiatric unit.
Ten days later, all parameters were normalized, especially CK, myoglobin, white blood cell count, GOT, and GPT.
After 10 more days, risperidone 2 mg daily was added and titrated to 3 mg daily. The patient improved and was discharged; 60 days later, he was in good clinical condition.
This patient presented NMS that was atypical in that muscular rigidity was absent during the periods with fever, (common with clozapine-related NMS), high CK, altered consciousness and autonomic dysregulation.
NMS occuring after a single dose of venlafaxine has been attributed to a dopamineinhibiting effect (2) or, alternatively, it has been explained as evidence of central serotonergic overdrive (3) . NMS and serotonin syndrome (SS) are often confused, and when considering their clinical overlap, many authors place NMS and SS in the spectrum of the same disorder (4), defined by some as "neurotoxic syndrome" (5) and also including catatony (6) .
Dantrolene's specificity of action remains unknown (7) ; however, in the case of our patient, adding dantrolene to lorazepam was crucial, even in the absence of rigidity. Early treatment with dantrolene prevented NMS from developing fully. Otherwise, the absence of rigidity is unrelated to this treatment, a characteristic of some NMS with better prognosis.
Fever, altered consciousness, and increased CK and myoglobin indicated treatment with dantrolene.
Vittorio Ferioli, MD Allesandra Manes, MD Chiara Melloni, MD Samuele Nanni, MD Giancarlo Boncompagni, MD Bologna, Italy
A Case of de Clérambault Syndrome in a Male Stalker With Paranoid Schizophrenia
Dear Editor: I describe a case of secondary erotomania in a 43-year-old Moroccan-Canadian single man, a former maintenance worker (collecting disability pension for many years) with a Grade 12 education. Although the syndrome is presumed to be rare in Western patients with schizophrenia, there is evidence for its high prevalence in schizophrenia patients of the paranoid subtype elsewhere. There is also evidence of a robust relation between grandiose delusions and erotomanic symptoms.
Case Report
De Clérambault syndrome, also known as erotomania, erotic paranoid state, delusions of passion, psychose passionelle, and in the DSM-IV-TR, as delusional disorder of the erotomanic type (1), is documented as an uncommon psychiatric syndrome (2) . It is an illness that involves the central delusional theme of being loved by another person. Efforts to contact the object of the delusion through telephone calls, letters, gifts, visits, and even surveillance and stalking are common. While most patients with this disorder in clinical samples are female, in forensic samples, the patients are mostly male. A classic feature of the disorder is that many actions of the target are interpreted by the patient as being paradoxical or contradictory (for example, the target may appear to hate the subject when she really loves him). The paradoxical interpretation of the rejection of the patient's overtures and of the lack of clear confirmation of his beliefs are viewed as a test of his own love for the target.
The patient was referred from an Ontario Provincial Court under the Mental Health Act for an assessment of his psychological status, pursuant to his being charged with criminal harassment over a 22-year period. He had dated the victim for 4 years prior to the commencement of his harassment, during which epoch he both physically and sexually assaulted her and psychologically and emotionally manipulated her. She then moved to another city, about 200 km away, and ended her relationship with him. He refused to accept this, sending her letters asking that he might live with her and her family. He continued to send packages, gifts, cards, and letters to her, many of which were sent from overseas after he moved back to Morocco with his parents for some time. Some contained menacing messages, and on several occasions, the patient ejaculated on the items and letters before sending them. The victim never responded to any of the messages. At one point, the patient was convicted of possessing a prohibited weapon after he attempted to intimidate the victim into entering his motor vehicle, using brass knuckles. After learning that she was married and had children, he began sending gifts for her children as well.
In addition to a mental status examination, the patient was neurologically examined with the Quick Neurological Screening Test II (QNST-II) and was intellectually and neurocognitively examined with the Test of Nonverbal Intelligence-3 (TONI-3) and the Cognistat Neurobehavioural Cognitive Status Examination (NCSE), respectively. He was also psychometrically examined with the Millon Clinical Multiaxial Inventory-II (MCMI-II), the Minnesota Multiphasic Personality Inventory-2 (MMPI-2), and the Personality Assessment Inventory (PAI). He was further examined with the Spousal Risk Assessment Guide (SARA).
No evidence of gross neurological disease or of neurocognitive impairment was uncovered, although the patient's level of fluid and nonverbal intellectual functioning appeared to be somewhat limited (that is, within the low average range at the 14th percentile). Further medical assessment also yielded unremarkable findings, other than a selfreport of occasional headaches and a documented history of acute dystonia with haloperidol. There was no history of alcohol or drug abuse. He was currently being treated psychopharmacologically with olanzapine (2.5 mg orally at bed time) and fluphenazine decanoate (15 mg IM).
The patient displayed no evidence of a formal thought disorder or of perceptual abnormalities (such as hallucinations) of any kind. However, he was blatantly delusional (for example, he falsely believed he had been raped at knifepoint by a coworker); he was grandiose (he believed he was an eminent inventor of children's toys, although he had never been recognized as such); and he evinced markedly narcissistic, obsessivecompulsive, and dependent personality features. Also indicated and underlying his intense oppositional resentment and anger were extreme cynicism and suspiciousness and (or) mistrust of others' motives, along with very low levels of heterosexual activity (his only intimate relationship was with the victim). The combination of impulsiveness, resentment, and good energy levels portended the likelihood that the patient might lash out at those whom he felt had slighted him in some way. The findings were also consistent with one of the prototypes of male spouse abusers, and the patient evinced several risk factors indicating an elevated risk for future spousal or romantic partner assault. The presence of delusions with an absence of prominent disorganized speech, disorganized or catatonic behaviour, or flat or inappropriate affect supported a diagnosis of schizophrenia of the paranoid subtype.
This case exemplifies previous findings of a relation between erotomanic symptoms and schizophrenia of the paranoid subtype and of a robust relation between grandiose delusions and erotomanic symptoms. It further exemplifies Kraepelin's original 1921 formulation, which classified erotomanic delusions as a subcategory of grandiose delusions (3, 4) . It remains unclear whether the currently presumed rarity of erotomanic symptoms in Western patients with schizophrenia is a result of a cultural disparity or a consequence of unreported characteristics of schizophrenia. This case illustrates that at least a systematic search for erotomanic symptoms, both during acute episodes of schizophrenia of the paranoid subtype and in the presence of grandiose delusions, should be conducted.
